Orion will publish Half-Year Financial Report for January-June 2020 on Friday, 17 July 2020 approximately at 12.00 noon EEST. The report and related presentation material and link to a live webcast and conference call details will be available here.
Orion Investor Relations have received several questions related to the coronavirus (COVID-19) pandemia and its impacts on Orion. We have listed here answers to some frequently asked questions.
The 2020 Annual General Meeting of Orion was held on Wednesday, 6 May 2020. The decisions and related material are available here.
Responsibility is one incentive when retail investors seek investments. Pharmaceuticals and healthcare is one of the most interesting sectors.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
|7/14/2020||191,501 Orion Corporation A shares converted into B shares|
|7/8/2020||Orion upgrades full-year outlook for 2020|
|6/25/2020||The cancellation of Orion Corporation shares entered in the Trade Register|
|6/15/2020||Orion Corporation has decided on cancellation of shares on the joint account|
|6/26/2020||Orion publishes Half-Year Financial Report for January-June 2020 on Friday 17 July 2020|
|6/26/2020||Distribution of Zoetis’ products in Sweden, Denmark and Norway by Orion to end after 2020|
|6/4/2020||Orion is developing an immuno-oncology (IO) drug discovery platform in the national research and innovation consortium Cancer IO|
|5/20/2020||Sales of darolutamide started in the EU and Japan – Orion receives total of EUR 28 million milestones|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Orion Corporation has been included in the globally recognised FTSE4Good Index.